©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2024; 30(5): 509-511
Published online Feb 7, 2024. doi: 10.3748/wjg.v30.i5.509
Published online Feb 7, 2024. doi: 10.3748/wjg.v30.i5.509
Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?
Matteo Tonnini, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy
Matteo Tonnini, Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy
Clara Solera Horna, Infectious Disease Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia 42123, Italy
Luca Ielasi, Department of Internal Medicine, Ospedale degli Infermi di Faenza, Faenza 48018, Italy
Author contributions: Tonnini M, Solera Horna C and Ielasi L conceived the manuscript; Tonnini M reviewed the literature and wrote the original draft; Tonnini M and Ielasi L reviewed and edited the manuscript; Solera Horna C supervised; and all authors read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Luca Ielasi, MD, Doctor, Department of Internal Medicine, Ospedale degli Infermi di Faenza, Viale Stradone, 9, Faenza 48018, Italy. luca.ielasi.kr@gmail.com
Received: November 1, 2023
Peer-review started: November 1, 2023
First decision: December 7, 2023
Revised: December 15, 2023
Accepted: January 11, 2024
Article in press: January 11, 2024
Published online: February 7, 2024
Processing time: 90 Days and 16.7 Hours
Peer-review started: November 1, 2023
First decision: December 7, 2023
Revised: December 15, 2023
Accepted: January 11, 2024
Article in press: January 11, 2024
Published online: February 7, 2024
Processing time: 90 Days and 16.7 Hours
Core Tip
Core Tip: In the last few years, the advent of several new therapies has characterized the therapeutic scenario of hematologic malignancies. There is now the open issue of assessing the risk of hepatitis B virus reactivation in these patients in order to decide which patients should undergo antiviral prophylaxis.